Mayne Pharma Investor Update and On-Market Share Buy-Back Program
Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “The past seven months have been a period of significant change for the Company, beginning with the October sale of our Greenville-based Metrics Contract Services, followed by the acquisition of the US commercial rights for TherapeuticsMD’s women’s health assets. With the recent sale of our retail generics business to Dr. Reddy’s, we are successfully executing on our strategy to become a more focused company, with growth potential while repaying debt, paying shareholders a special dividend, and strengthening our cash position in the process.”
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Mayne Pharma Group Limited a question about this update.